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A b s t r a c t
Introduction: Invasive coronary angiography (CAG), the ‘gold standard’ in coronary artery disease (CAD) diagnosis, requires 
hospitalization, is not risk-free, and engages considerable healthcare resources.
Aim: To assess recent (throught out 10 years) evolution of ‘significant’ (≥ 50% stenosis(es)) CAD prevalence in subjects under-
going CAG for CAD diagnosis in a high-volume tertiary referral center.
Material and methods: Anonymized medical records were compared from the last vs. the first 2-years of the decade (June 2007 
to May 2018). Referrals for suspected CAD were 2067 of 4522 hospitalizations (45.7%) and 1755 of 5196 (33.8%) respectively 
(p < 0.001).
Results: The median patient age (64 vs. 68 years) and the prevalence of heart failure (24.1% vs. 42.2%) increased significantly 
(p < 0.001). The CAG atherosclerotic lesions, for all stenosis categories (< 50%; ≥ 50%; ≥ 70%; occlusion(s)), were significantly more 
prevalent in men. The proportion of subjects with any atherosclerosis on CAG increased (80.7% vs. 77.6%, p = 0.015). However, in 
the absence of any gross change in, for instance, the fraction of women (40.4% vs. 41.8%), the proportion of CAGs with significant 
CAD (lesion(s) ≥ 50%) decreased from 55.2% in 2007/2008 to below 1 in every 2 angiograms (48.9%) in 2017/2018 (p < 0.001). This 
unexpected finding occurred consistently across nearly all CAG referral categories.
Conclusions: Despite more advanced age and a higher proportion of subjects with ‘any’ coronary atherosclerosis on CAG, the 
likelihood of a ‘negative’ angiogram (lesion(s) < 50%; no further evaluation/intervention) has increased significantly over the last 
decade. The exact nature of this phenomenon requires further investigation, particularly as a reverse trend would be expected with 
the growing role (and current high penetration) of contemporary non-invasive diagnostic tools to rule out significant CAD.
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S u m m a r y
Invasive coronary angiography (CAG), the ‘gold standard’ in coronary artery disease (CAD) diagnosis, requires hospitaliza-
tion, is not risk-free, and engages considerable healthcare resources. We hypothesized that the current high penetration of 
non-invasive tools to rule out significant CAD (such as computed tomography angiography, single photon emission computed 
tomography or stress echocardiography) would lead to a  reduction in CAGs showing an absence of significant lesions. By 
comparing the outcome of CAGs in the final vs. first 2 years of the last decade, we found – surprisingly – that despite more 
advanced patient age and a higher proportion of subjects with ‘any’ coronary atherosclerosis on CAG, the likelihood of a ‘neg-
ative’ angiogram has increased significantly. Such findings may have implications for patient management and healthcare 
resources utilization.
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Introduction
Cardiovascular diseases, responsible for nearly half 
of all deaths, are the main cause of death in Poland [1]. 
Among cardiovascular deaths, coronary artery disease 
(CAD) takes the biggest share (23.0% of all deaths in 
2013; n = 40 869) [1]. Although not uncommon in mid-
dle-aged subjects, CAD affects mainly older patients, 
and it is seen more often in males than females [1]. The 
proportion of people aged over 65 is currently growing 
(and will grow further, by one fifth, by 2050) [1], thus 
significantly increasing the population of patients with 
cardiovascular diseases and increasing projected cardio-
vascular deaths [1]. Therefore prevention of CAD morbid-
ity and mortality remains a crucial target, not only at the 
individual patient-physician level, but also at the level of 
national healthcare policy [1, 2].
In general, coronary artery lesions with below 50% 
diameter stenosis (considered angiographically ‘insignif-
icant’) require no interventional management but rath-
er modification of risk factors and pharmacotherapy to 
prevent or minimize lesion progression and the risk of 
lesion destabilization [3]. On the other hand, patients 
with lesion(s) ≥ 50% (considered angiographically ‘signif-
icant’ CAD [4–8]) may benefit from procedural interven-
tion (particularly in the case of documented myocardial 
ischemia [3]) and lesions ≥ 70% are usually considered to 
require intervention [3]. Thus unequivocal determination 
of CAD severity continues to play a fundamental role in 
clinical decision-making in contemporary cardiology. 
Invasive coronary angiography (CAG) remains the ‘gold 
standard’ in diagnosing CAD [3]. At present, nearly 55 000 
diagnostic coronary angiograms are performed in Poland 
annually at the cost (inclusive of hospitalizations) of ca. 
110 000 000 PLN (ca. 26 000 000 Euros) [9]. Although 
highly accurate, CAG is associated with X-ray exposure, 
use of a contrast medium, and is not free of complications 
[10]. The acceptable accuracy of non-invasive modalities 
(such as single-photon emission tomography, SPECT [11], 
computed tomography angiography [12] or stress echo-
cardiography [13]) to rule out significant CAD [12] has led 
to increased adoption of these techniques in everyday 
clinical practice on both an outpatient and inpatient basis 
[14–17]. As all-comer patient data, by removing the bias 
of trial-non-represented patients and under-reporting bias 
[18], are critical in determining the practical role of new 
technologies [19], we hypothesized that high-volume ter-
tiary referral center all-comer data from the last decade 
would provide evidence for (1) reduction in CAG use to de-
termine CAD in all-comer hospitalizations, and (2) reduc-
tion in the proportion of those CAGs that show an absence 
of significant CAD.
Aim
This study was undertaken to assess the real-life evo-
lution of CAG use for suspected CAD and the evolution of 
CAG angiographic results in a high-volume tertiary refer-
ral center by comparing large-volume all-comer samples 
from the beginning and the end of the decade.
Material and methods
We retrospectively investigated anonymized medical 
records of all consecutive hospital admissions to the Jagi-
ellonian University Department of Cardiac and Vascular 
Disease at John Paul II Hospital, Kraków, Poland, in two 
distinct 2-year periods: at the beginning and the end of 
the 2007/2008–2017/2018 decade. The first sample con-
sisted of patients admitted to our institution from 1 June 
2007 to 31 May 2009 (period A); the second one included 
those hospitalized from 1 June 2016 to 31 May 2018 (peri-
od B). The 2-year (rather than typical 1-year) samples were 
chosen to minimize the likelihood of chance variations 
that might affect the study findings. For each period, the 
total number of admissions and the number of admissions 
including CAG for definitive CAD diagnosis (i.e., the actual 
study group) were determined. The non-study group in-
volved, for both study periods, the patients hospitalized 
without CAG. Those included, amongst others, admissions 
for coronary revascularization following CAG performed 
elsewhere or admissions for another stage of revascular-
ization, admissions for heart failure (HF) management in 
patients with already known coronary status, grown-up 
congenital heart disease admissions, admissions for ar-
rhythmia diagnosis and management or hospitalizations 
for advanced diagnostic imaging or therapeutic and re-
search procedures (e.g., pulmonary artery angioplasty or 
myocardial regeneration therapy) in patients considered 
not to require CAG [20–25]. A  significant proportion of 
these non-study patients had previously determined CAG 
status or had undergone non-invasive testing to rule out 
significant CAD or were considered not to require coronary 
evaluation due to, for instance, young age [20]. 
All referrals for clinically-indicated invasive CAD diag-
nosis were grouped into 5 categories according to the 
principal referral diagnosis. These (non-overlapping) la-
bels/categories were the following: 
1. Stable unaccompanied CAD (‘unaccompanied’ un-
derstood as absence of any of the diagnostic labels 
below; cf., 2–5).
2. Acute coronary syndrome (ACS, including ST-eleva-
tion and non ST-elevation acute myocardial infarction 
and unstable angina).
3. Vascular disease (involving, in most cases, determi-
nation of the coronary status prior to vascular sur-
gery or endovascular management of aortic, periph-
eral vascular or carotid disease).
4. Valvular heart disease (VHD; NB this category also 
included other, uncommon, conditions requiring cor-
onary status determination prior to cardiac surgery).
5. Structural heart disease (mostly patients diagnosed 
for atrial septal defect, ASD, or permanent foramen 
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ovale (PFO) management or left atrial appendage ex-
clusion) and pulmonary hypertension (PH) diagnosis 
and/or intervention (SHD/PH category).
Pilot analysis showed that heart failure (HF) could not 
be considered a separate referral category because of its 
significant overlap with the 5 exclusive categories giv-
en above. Nevertheless, because of its major individual 
and social impact [14, 15], the HF referral co-label was 
searched and recorded in each case to enable compari-
son of HF prevalence in patients undergoing CAG in the 
two studied periods. 
According to the absence/presence of angiographi-
cally depicted lesions in a major epicardial vessel, CAGs 
were classified as showing the following: no CAD (nor-
mal coronary arteries, no luminal irregularity [26]) or CAD 
presence (‘any’ CAD) that was inclusive of stenosis(es) 
< 50% of the lumen diameter, stenosis(es) ≥ 50%, steno-
sis(es) ≥ 70%, occlusion(s) [3–8]. In addition, angiographic 
prevalence of the left main coronary artery (LM) stenosis 
≥ 50% [3] was evaluated. ‘Significant’ CAD was defined, 
consistent with the existing convention, as the presence 
of atherosclerotic lesion(s) with ≥ 50% diameter stenosis 
[3–7]. In contrast, a ‘negative’ angiogram was defined as 
absence of lesion(s) ≥ 50% as this is grossly consistent 
with lack of indication for revascularization and absence 
of the need for further intravascular evaluation in the 
context of potential revascularization [3].
Statistical analysis
The frequencies of qualitative variables were present-
ed as percentages and compared using the χ2 test of pro-
portions for categorical variables with Yates’ correction, 
if applicable. Statistical analysis was performed using 
StatSoft Statistica 13.1 software for Windows (StatSoft 
Inc., Tulsa, OK, USA). P-values of < 0.05 were considered 
statistically significant.
Results
There were 4522 hospitalizations in period A  and 
5196 hospitalizations in period B (Table I and Figure 1; 
note the increase in hospitalization volume by 14.9%). 
The study cohort (CAG patients) included 2067 (834, 
40.4% females) in period A  and 1755 patients (734, 
41.8% females) in period B. The proportion of patients 
undergoing CAG decreased from 45.7% in period A 
to 33.8% in period B (p < 0.001; Figure 1 A; absolute 
reduction by 11.9%, relative reduction by 26.1%). The 
median age of presentation increased by 4 years, from 
64 (Q1–Q3: 56–72) to 68 years (Q1–Q3: 61–75) respec-
tively (p < 0.001). The structure of CAG patients according 
to their referral diagnosis is shown in Figure 1 B, indicating 
no striking differences in the proportion of key categories 
(stable CAD – 52.8% vs. 50.8%; ACS 27.4% vs. 28.0%). 
However, a ≈40% increase in VHD and SHD/PH catego-
ries occurred at the end vs. beginning of the decade at 
the expense of CAG in vascular disease coronary eval-
uation (the latter became partly managed in a new de-
partment of the hospital). The proportion of HF, however, 
grew profoundly – from 24.1% of CAG patients in period A 
to 42.2% in period B (absolute increase by 18.1%, relative 
increase by 75.1%; p< 0.001; Figure 1 C). 
Males were in general more prevalent across the re-
ferral categories (Table I) and the male gender was con-
sistently higher (than the female sex) represented in all 
atherosclerotic lesion subsets; i.e., ≥ 50% stenosis, ≥ 70% 
stenosis, occlusion and LM stenosis in the groups (Table I). 
Analysis as per the specific referral categories showed 
that the overall differences in the findings between 
period B vs. period A were driven mostly by unaccompa-
nied stable CAD and ACS (Table I, Figure 2). 
The finding of a  ‘positive’ angiogram (defined, con-
sistent with the fundamental clinical decision-making 
threshold, as presence of lesion(s) ≥ 50% diameter ste-
nosis) decreased between period B and period A by 6.3% 
(p < 0.001, relative reduction by 11.4%, Figure 2). Data 
regarding the prevalence of coronary occlusion(s) and LM 
disease are shown in Table I and in Figure 2. 
Discussion
The fundamental new findings from this work, in rela-
tion to the pattern of first-time CAGs for suspected CAD 
in a high-volume tertiary referral center over a decade, 
are the following: 
Despite an increase in the overall hospitalizations 
volume by 14.9%, a reduction in referrals for suspected 
CAD occurred (from 45.7% to 33.8%; p < 0.001, Figure 1);
The proportion of CAGs depicting significant CAD 
(defined as presence of lesion(s) ≥ 50%) decreased from 
55.2% in 2007/2009 to below 1 in every 2 angiograms in 
2016/2018 (48.9%, p < 0.001). This unexpected finding 
was seen across nearly all CAG referral subgroups (Fig-
ure 2) and results for the prevalence of lesion(s) ≥ 70% 
were fully consistent (absolute reduction by 5.0% – from 
48.8% to 43.8%, p = 0.022, relative reduction by 10.3%, 
Figure 2).
Other important observations, consistent with current 
CAD trends [1], include a significant increase in the medi-
an age (64 vs. 68 years) and the prevalence of heart failure 
(24.1% vs. 42.2%) increased significantly (p < 0.001 for 
both) while the proportion of women admitted for clin-
ically indicated CAG remained similar (40.4% vs. 41.8%; 
Table I, Figure 1). As expected [6, 27], atherosclerotic cor-
onary artery lesions, for all stenosis categories (i.e., any 
angiographic atherosclerosis, lesion(s) ≥ 50% , lesion(s) 
≥ 70%, occlusion(s), left main (LM) coronary artery steno-
sis ≥ 50%) were more prevalent in males (Table I). 
The most striking finding from the present study is 
a  significant increase, for the last two versus the first 
2 years of the decade, in the likelihood of a  ‘negative’ 
angiogram (understood as absence of lesion(s) ≥ 50%, 
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Table I. Characteristics of the overall study cohort (A) and per suspected CAD referral categories (B)
A
Parameter Period A Period B B vs. A
P-valueTotal  
(n = 2067)
Men  
(n = 1233)
Women
(n = 834)
P-value Total
(n = 1755)
Men
(n = 1021)
Women
(n = 734)
P-value
Median age 64 62 66 < 0.0001 68 66 69.5 < 0.0001 < 0.0001
Any atherosclerosis 1603 (77.6%) 1026 (83.2%) 577 (69.2%) < 0.0001 1417 (80.7%) 884 (86.6%) 275 (72.6%) < 0.0001 0.0158
≥ 50% stenosis/es 1140 (55.2%) 796 (64.6%) 344 (41.2%) < 0.0001 859 (48.9%) 604 (59.2%) 255 (34.7%) < 0.0001 0.0001
≥ 70% stenosis/es 1008 (48.8%) 714 (57.9%) 294 (35.3%) < 0.0001 769 (43.8%) 551 (54.0%) 218 (29.7%) < 0.0001 0.0022
Occlusion/s 517 (25.0%) 405 (32.8%) 112 (13.4%) < 0.0001 325 (18.5%) 239 (23.4%) 86 (11.7%) < 0.0001 < 0.0001
LM stenosis 48 (2.2%) 37 (3.0%) 11 (0.5%) 0.0128 58 (3.3%) 47 (4.6%) 11 (1.5%) 0.0003 0.0810
B
Parameter Period A Period B B vs. A
P-valueTotal Men Women P-value Total Men Women P-value
Unaccompanied 
stable CAD:
(n = 1120) (n = 64) (n = 456) (n = 892) (n = 497) (n = 395)
Median age 64 63 66 < 0.0001 68 67 69 0.0001 < 0.0001
Any atherosclerosis 820 (73.2%) 522 (78.6%) 298 (65.4%) < 0.0001 703 (78.8%) 428 (86.1%) 275 (69.6%) < 0.0001 0.0036
≥ 50% stenosis/es 528 (47.1%) 372 (56.0%) 156 (34.2%) < 0.0001 364 (40.8%) 254 (51.1%) 110 (27.9%) < 0.0001 0.0045
≥ 70% stenosis/es 467 (41.7%) 330 (49.7%) 137 (30.0%) < 0.0001 313 (35.1%) 219 (44.1%) 94 (23.8%) < 0.0001 0.0025
Occlusion/s 226 (20.2%) 183 (27.6%) 43 (9.4%) < 0.0001 109 (12.2%) 79 (15.9%) 30 (7.6%) < 0.0001 < 0.0001
LM stenosis 32 (2.9%) 23 (3.5%) 9 (2.0%) 0.1977 25 (2.8%) 22 (4.4%) 3 (0.8%) 0.0001 0.9505
ACS: (n = 528) (n = 351) (n = 177) (n = 491) (n = 326) (n = 165)
Median age 62 60 69 < 0.0001 67 65 69 < 0.0001 0.0002
Any atherosclerosis 484 (91.7%) 333 (94.9%) 151 (85.3%) 0.0002 440 (89.7%) 305 (93.6%) 135 (81.8%) < 0.0001 0.2599
≥ 50% stenosis/es 438 (83.0%) 312 (88.9%) 126 (71.2%) < 0.0001 373 (76.0%) 276 (84.7%) 97 (58.8%) < 0.0001 0.0057
≥ 70% stenosis/es 422 (79.9%) 304 (86.6%) 118 (66.7%) < 0.0001 356 (72.5%) 268 (82.2%) 88 (53.3%) < 0.0001 0.0054
Occlusion/s 228 (43.2%) 173 (49.3%) 55 (31.1%) 0.0001 180 (36.7%) 136 (41.7%) 44 (26.7%) 0.0011 0.0338
LM stenosis 9 (1.7%) 8 (2.3%) 1 (0.6%) 0.2799 27 (5.5%) 22 (6.8%) 5 (3.0%) 0.1342 0.0010
Vascular disease: (n = 234) (n = 138) (n = 96) (n = 140) (n = 92) (n = 48)
Median age 68 68 68 0.9025 70 70 70.5 0.5569 0.0059
Any atherosclerosis 206 (88.1%) 124 (89.9%) 82 (85.4%) 0.4098 126 (90.0%) 86 (93.5%) 40 (83.3%) 0.1091 0.6792
≥ 50% stenosis/es 136 (58.1%) 91 (65.9%) 45 (46.9%) 0.0036 75 (53.6%) 53 (57.6%) 22 (45.8%) 0.2512 0.4528
≥ 70% stenosis/es 91 (38.9%) 64 (46.4%) 27 (28.1%) 0.0049 66 (47.1%) 48 (52.2%) 18 (37.5%) 0.1409 0.1175
Occlusion/s 51 (21.8%) 41 (29.7%) 10 (10.4%) 0.0004 26 (18.6%) 20 (21.7%) 6 (12.5%) 0.2690 0.5392
LM stenosis 5 (2.4%) 5 (3.6%) 0 (0.0%) 0.1540 5 (3.6%) 2 (2.2%) 2 (4.2%) 0.8907 0.9272
VHD: (n = 114) (n = 46) (n = 68) (n = 128) (n = 61) (n = 67)
Median age 65 63 66 0.0656 71 68 73 0.0689 0.0011
Any atherosclerosis 67 (58.8%) 30 (65.2%) 37 (54.4%) 0.3391 97 (75.8%) 44 (72.1%) 53 (79.1%) 0.4757 0.0047
≥ 50% stenosis/es 23 (20.2%) 10 (21.7%) 13 (19.1%) 0.9169 21 (24.2%) 15 (24.6%) 16 (23.9%) 0.9101 0.5489
≥ 70% stenosis/es 17 (14.9%) 8 (17.4%) 9 (13.2%) 0.7315 21 (16.4%) 10 (16.4%) 11 (16.4%) 0.8141 0.8872
Occlusion/s 7 (6.1%) 3 (6.5%) 4 (5.9%) 0.7963 7 (5.5%) 2 (3.3%) 5 (7.5%) 0.5153 0.9582
LM stenosis 1 (0.9%) 0 (0.0%) 1 (1.5%) 0.8434 0 (0.0%) 0 (0.0%) 0 (0.0%) 0.9537
SHD/PH: (n = 71) (n = 34) (n = 37) (n = 104) (n = 45) (n = 59)
Median age 57 54 61 0.0081 65 62 68 0.0007 0.0001
Any atherosclerosis 26 (36.6%) 17 (50.0%) 9 (24.3%) 0.0459 51 (49.0%) 21 (46.7%) 30 (50.9%) 0.8223 0.1041
≥ 50% stenosis/es 15 (21.1%) 11 (32.4%) 4 (10.8%) 0.0537 16 (15.4%) 6 (13.3%) 10 (17.0%) 0.8165 0.4381
≥ 70% stenosis/es 11 (15.5%) 8 (23.5%) 3 (8.1%) 0.1427 11 (10.6%) 5 (11.1%) 6 (10.2%) 0.8673 0.4648
Occlusion/s 5 (7.0%) 5 (14.7%) 0 (0.0%) 0.0506 3 (4.6%) 2 (4.4%) 1 (1.7%) 0.8113 0.3553
LM stenosis 1 (1.4%) 1 (3.9%) 0 (0.0%) 0.9660 2 (1.9%) 1 (2.2%) 1 (1.7%) 0.5985 0.7373
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grossly indicating no indication for further intravascular 
evaluation or intervention that might affect the patient’s 
symptomatic status and/or prognosis [3]). Interestingly, 
this occurred despite a significantly smaller proportion of 
subjects undergoing clinically indicated CAG (Figure 1 A) 
that may be per se considered consistent with an in-
creased role of non-invasive tests to rule out significant 
CAD [28]. However, an opposite trend might be anticipated 
with a significantly more advanced patient age in period B 
(median 68 vs. 64 years) and with significant increase (by 
3.1%, p < 0.001) in the angiographic finding of ‘any’ ath-
erosclerosis (a  consistent across-the-referral-categories 
growth driven by an increase in prevalence of atheroscle-
rotic lesions < 50%).
The exact nature of this phenomenon requires fur-
ther investigation, particularly as a  reverse trend (driven 
by contemporary ruling-out of non-significant CAD largely 
prior to the stage of hospital admission/CAG) should be 
expected with an increasing penetration (and role in de-
cision-making) of the current generation of non-invasive 
diagnostic tools to rule out significant CAD. Those include, 
used today routinely on an out-patient and in-patient 
A
B
C
Figure 1. Graphic representation of key clinical 
characteristics of the study groups. A – Proportion 
of patients undergoing CAG in period A (left, total 
number of hospitalizations – 4522) and period B 
(right, total number of hospitalizations – 5196). 
B – Structure of referrals for suspected CAD in pe-
riod A (left) and period B (right). C – Prevalence of 
heart failure as an accompanying referral diagno-
sis in period A and period B
Period A (n = 2067 CAGs)
Period A
45.7%
33.8%
Period B (n = 1755 CAGs)
Period B
ACS 27.4%
Vascular 
disease 
11.0%
VHD  
5.4%
SHD/PH 
3.3%
Unaccom-
panied 
stable 
CAD 
52.8%
ACS 28.0%
Vascular 
disease 
8.0%
VHD 
7.3%
SHD/PH 
5.9%
Unaccom-
panied 
stable 
CAD 
50.8%
Pe
rc
en
ta
ge
100
80
60
40
20
0
 Period A Period B
p < 0.0001
24.1%
42.0%
Jakub Chmiel et al. Evolution of invasive diagnostics in CAD
252 Advances in Interventional Cardiology 2018; 14, 3 (53)
100
80
60
40
20
0
100
80
60
40
20
0
100
80
60
40
20
0
10
5
0
–5
–10
10
5
0
–5
–10
10
5
0
–5
–10
Pr
ev
al
en
ce
 (
%
)
Pr
ev
al
en
ce
 (
%
)
Pr
ev
al
en
ce
 (
%
)
Ch
an
ge
 (
pe
ri
od
 B
 v
s.
 A
) 
(%
)
Ch
an
ge
 (
pe
ri
od
 B
 v
s.
 A
) 
(%
)
Ch
an
ge
 (
pe
ri
od
 B
 v
s.
 A
) 
(%
)
 Any  ≥ 50% ≥ 70% Occlusion/s
 atherosclerosis stenosis/es stenosis/es
             Period A          Period B
 Any  ≥ 50% ≥ 70% Occlusion/s
 atherosclerosis stenosis/es stenosis/es
             Period A          Period B
 Any  ≥ 50% ≥ 70% Occlusion/s
 atherosclerosis stenosis/es stenosis/es
             Period A          Period B
 Any  ≥ 50% ≥ 70% Occlusion/s
 atherosclerosis stenosis/es stenosis/es
 Any  ≥ 50% ≥ 70% Occlusion/s
 atherosclerosis stenosis/es stenosis/es
 Any  ≥ 50% ≥ 70% Occlusion/s
 atherosclerosis stenosis/es stenosis/es
p = 0.0158
p = 0.0036
p = 0.2599
77.6
73.2
91.7
3.1
5.6
80.7
78.8
89.7
55.2
47.1
83.0
48.9
40.8
76.0
–6.3
–6.3
–7.0
–6.5
–8.0
–6.5
–2.0
–5.0
–6.6
–7.4
48.8
41.7
79.9
43.8
35.1
72.5
25.0
20.2
43.2
18.5
12.2
36.7
p = 0.0001
p = 0.0045
p = 0.0057
p = 0.0022
p = 0.0025
p = 0.0054
p < 0.0001
p < 0.0001
p = 0.0338
A
B
1
2
Figure 2. Angiographic prevalence (left) of coronary atherosclerotic lesions in CAGs performed in period A and 
period B and the change (right) in period B versus period A. A – Data for the whole study population. B – Data 
for specific referral diagnoses grouped into five categories (1 – unaccompanied stable CAD, 2 – ACS, 3 – vascu-
lar disease, 4 – VHD, 5 – SHD/PH). See text for abbreviations
basis, CT angiography, SPECT, and/or stress echo [11–16, 
28–30]. Reasons beyond this unexpected finding, with its 
implications for patient management and healthcare re-
sources utilization, are likely to be several-fold.
First, although the role of current generation non-in-
vasive tests to rule out significant CAD has no doubt 
increased [28], and contemporary cardiology currently 
operates largely in the era of ‘functional ischemia’ [3], 
there is increasing understanding that non-invasive tests 
and imaging modalities (although generally adopted 
and generally useful in clinical decision-making practice 
[11–16, 28–30]) cannot universally replace CAG due to 
their patient population-dependent, device-dependent, 
and reporter-dependent issues leading to different op-
timal performance ranges and a (varying) proportion of 
the tests being non-diagnostic [12, 28, 31, 32]. For these 
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Figure 2. Cont. 
reasons, the clinician’s selection of ‘the best’ diagnostic 
technique for any given patient to rule in or rule out sig-
nificant CAD remains challenging [28]. Moreover, a signif-
icant proportion of patients with ‘negative’ angiograms 
(up to 2/3 [27] exhibit myocardial ischemia not only on 
clinical presentation but also on imaging) [33]. Micro-
vascular angina as well as vasospastic angina do require 
disease-specific management [34] and utilize significant 
healthcare resources [35], and a  ‘negative’ CAG is the 
backbone of this diagnosis [27, 33, 34]. Thus, for today, it 
would be wrong to consider all ‘negative’ angiograms an 
unnecessary undertaking [36].
Increased prevalence of CAD decreases specificity of 
non-invasive tests, and – in a number of clinical scenarios 
in clinical practice – CAG is still performed after a non-inva-
sive test rules out ‘significant’ CAD [12, 30, 31]. The timing 
of performing the (selected) non-invasive test(s) to rule out 
significant CAD has a profound effect on the data such as 
the one reported in the present study. We expect that most 
‘rejections’ from CAG would occur at the pre-hospital state, 
but those also occur during hospitalization; thus we cannot 
rule out a  considerable contribution of this population to 
the non-CAG patients, influencing the proportion between 
those subjected vs. not subjected to CAG (cf., Figure 1 A). 
3
4
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Another potentially important contribution to the 
temporal change in CAG referrals and outcome pattern 
observed in the present study may be linked to the pro-
found increase in HF hospitalizations – both with and 
without CAG. In Europe and North America ≈30–50% of 
HF patients exhibit ‘significant’ CAD [15, 29]. Although 
‘simple’ algorithms to rule out significant CAD in HF pa-
tients have been proposed based on evaluation of mod-
erately sized populations [29, 37], they are not routine-
ly applied and for the majority of HF patients there is 
a drive towards a definitive CAD diagnosis – i.e., perform-
ing CAG irrespective of the non-invasive tests that may 
(or may not) have taken place before. Thus the increased 
HF population (Figure 1) might contribute to the increase 
in ‘negative’ angiograms (Figure 2).
It is plausible that the growth of primary cardiology 
centers with CAG facilities may have influenced the refer-
ral structure to the tertiary centers, resulting in a higher 
proportion of (for a  range of medical reasons) ‘non-ob-
vious’ (rather than ‘obvious’) patients being currently 
evaluated in the tertiary centers. Assessment of the mag-
nitude of this phenomenon, although extremely interest-
ing and potentially impactful, is beyond the scope of our 
present work. 
The pattern change depicted in the present study 
(growth of the proportion of patients with ‘any’ athero-
sclerosis driven by ‘non-significant’ lesions but fewer pa-
tients with ‘significant’ CAG lesions) may also result, in 
part, from the efficacy of aggressive pharmacologic and 
non-pharmacologic prevention in increased-risk subjects 
[2], leading to a modification in the course of the disease. 
Thus the present findings may be considered as a poten-
tial signal of the surfacing efficacy of adopting aggressive 
cardiovascular prevention measures.
It is worthwhile to realize that, despite the current era 
of ‘functional ischemia’ [3], there are credible contempo-
rary data indicating that the structural burden of coro-
nary disease (including angiographic lesions ≥ 50% [7]) 
is important – and that it may be prognostically far more 
relevant than the functional ischemia [7]. This further 
confirms that the primary cut-off of ‘50% diameter ste-
nosis’ between ‘insignificant’ and ‘significant’ coronary 
lesions used in our study (similar to a number of previous 
ones [3–7]) appears, at the present stage of knowledge, 
appropriate. Indeed, the anatomic burden of atheroscle-
rotic disease (using the > 50% angiographic lesion sever-
ity cutoff) was recently demonstrated to be a consistent 
predictor of death and myocardial infarction whereas the 
ischemic burden was not [7]. 
Previous research on cardiovascular disease tempo-
ral trends in Poland has been focused on ACS with their 
clinical characteristics, treatment strategies, and out-
comes [38, 39], leading to a series of crucial data used to 
improve patient care and utilization of resources in this 
specific patient cohort. In contrast, trends in stable CAD 
all-comer patient population characteristics and CAG 
outcomes have remained largely undetermined. Thus 
our work fills an important gap in the knowledge. Fur-
thermore, the present study importantly supplements re-
cent analysis from the Silesian Cardiovascular Database 
(SILCARD registry [40]). While the primary interest of 
SILCARD (which used pooled data from the primary, sec-
ondary and tertiary cardiology referral centers in Silesia, 
Poland) were the causes of hospitalization and progno-
sis in patients with cardiovascular disease in 2006–2014 
[40], our work is focused on the angiographic outcomes 
in those hospitalized patients who underwent CAG. Im-
portantly, both studies are consistent in their indication 
of a  change in the population characteristics of hospi-
talized subjects, including a more advanced age (by 3–4 
years in SILCARD [40]) and increasing prevalence of HF 
(in SILCARD absolute growth by 4.8%, relative growth by 
29.3% [40]). Furthermore, the gender differences depict-
ed in the present study (Table I) are similar to those in 
SILCARD [40] and those reported in other populations 
[4, 6, 26, 38, 39, 41, 42] and are thus consistent with 
internal integrity of the present data.
Finally, it needs to be noted that an increase in the 
‘negative’ angiogram prevalence (Figure 2) does not nec-
essarily indicate a  trend that should automatically call 
for its reversal. Rather, this may indicate an increase in 
the proportion of patients who, for a  number of clinical 
reasons, require a  definitive diagnosis of their coronary 
status. Our findings regarding the beginning of the last 
decade are broadly consistent with data from the United 
States Veterans Affairs Healthcare System, where up to 
48.5% of CAGs were ‘negative’ in 2007–2010 [43], but the 
temporal evolution in the US is unknown at present. Inter-
estingly, in the US the numbers of CAGs appear constant 
over time (with CAG patients, similar to our results, getting 
older) [44] while rates of coronary revascularization have 
seen a significant decline in the last decade [45].
Limitations
While this work presents an accurate capture of the 
data from medical records in a  large-volume center, one 
major limitation is that it is presently unknown whether, 
and to what extent, the findings are applicable to other 
tertiary cardiovascular referral centers. Although any ma-
jor differences (at least within Poland, which has a simi-
lar patient referral structure across the country) and one 
(public) insurer are unlikely, some differences in the clinical 
characteristics of admission cohorts may exist in relation 
to specific interests and locations of expertise. Further-
more, it is unknown at present whether (and to what ex-
tent) trends similar to those depicted in the present study 
have occurred in the primary referral centers with CAG ca-
pacities. The growth of primary centers with CAG facilities, 
on the other hand, is likely to have affected changes in re-
ferrals to tertiary centers (including ours), affecting chang-
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es in the proportion of patients subjected to CAG in the 
tertiary centers, and – possibly – also the CAG outcomes in 
the primary vs. tertiary centers. For these reasons, a large-
scale overview of changes in the referral structure and CAG 
results across the country would be welcomed. 
Another limitation is that we did not capture any 
detailed information regarding hospitalizations without 
performing CAG. The potential temporal changes in the 
non-CAG patients may affect findings in the CAG cohorts. 
For instance, an increase in the adoption of non-invasive 
tests to rule out significant CAD would be expected to re-
sult in reduced CAG referrals. Also, there is evidence from 
other healthcare systems that changes in reimbursement 
policies may affect patient referrals and clinical charac-
teristics of the hospitalized patients [46–48]. It is un-
known whether (and to what extent) this would contrib-
ute to temporal changes observed in the present study.
Finally, our present work did not involve re-review of 
the angiograms in a corelab fashion. Coronary stenosis 
severities, however, taken into consideration in the pres-
ent study were routinely re-reviewed within the patient 
management teams including several interventionalists, 
and were the ones used in patient decision-making, re-
sulting in their relevance to clinical practice. Indeed, any 
corelab re-review would be impractical in the present 
sample involving nearly 4000 angiograms, and we con-
sider it highly unlikely that this could yield any greatly 
different angiographic outcomes. 
Conclusions
Despite more advanced patient age and a higher pro-
portion of subjects with ‘any’ coronary atherosclerosis on 
CAG, the likelihood of a  ‘negative’ angiogram (lesion(s) 
< 50%, indicating no further evaluation/intervention) has 
increased significantly over the last decade. Consistent 
findings occurred for the reduced prevalence of angio-
grams depicting lesion(s) ≥ 70%. The exact nature of this 
phenomenon requires further investigation, particularly 
as a reverse trend would be expected with a growing role 
(and current high penetration) of contemporary non-in-
vasive diagnostic tools to rule out significant CAD. Bet-
ter strategies for risk stratification are needed to inform 
clinical decisions and to increase the diagnostic yield of 
CAG in routine clinical practice. These findings may have 
implications for patient management by clinicians on the 
one hand and, on the other, for healthcare resources uti-
lization and insurance policies. 
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